135 related articles for article (PubMed ID: 38724815)
1. Modulators of the Nrf2 Signaling Pathway Enhance the Cytotoxic Effect of Standard Chemotherapeutic Drugs on Organoids of Metastatic Colorectal Cancer.
Razumovskaya AV; Silkina MO; Nikulin SV; Tonevitsky AG; Alekseev BY
Bull Exp Biol Med; 2024 Mar; 176(5):703-708. PubMed ID: 38724815
[TBL] [Abstract][Full Text] [Related]
2. Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells.
Frerker B; Bock F; Cappel ML; Kriesen S; Klautke G; Hildebrandt G; Manda K
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373535
[TBL] [Abstract][Full Text] [Related]
3. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Ren D; Villeneuve NF; Jiang T; Wu T; Lau A; Toppin HA; Zhang DD
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1433-8. PubMed ID: 21205897
[TBL] [Abstract][Full Text] [Related]
4. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway.
Xiang Y; Ye W; Huang C; Yu D; Chen H; Deng T; Zhang F; Lou B; Zhang J; Shi K; Chen B; Zhou M
Oxid Med Cell Longev; 2018; 2018():2360427. PubMed ID: 29849873
[TBL] [Abstract][Full Text] [Related]
5. HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
Verdina A; Di Segni M; Amoreo CA; Sperduti I; Buglioni S; Mottolese M; Di Rocco G; Soddu S
Oncol Rep; 2021 Mar; 45(3):899-910. PubMed ID: 33650652
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Grivicich I; Mans DR; Peters GJ; Schwartsmann G
Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C.
Cheng C; Yuan F; Chen XP; Zhang W; Zhao XL; Jiang ZP; Zhou HH; Zhou G; Cao S
Biomed Pharmacother; 2021 Oct; 142():111652. PubMed ID: 34112534
[TBL] [Abstract][Full Text] [Related]
8. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM
J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064
[TBL] [Abstract][Full Text] [Related]
9. Patient-derived Organoid Model for Predicting the Chemoresponse in Patients With Colorectal Cancer.
Yi K; Park SH; Kim DU; Jeon DY; Lee HJ; Song GA; Jo HJ; Baek DH; Han JH; Lee BC
In Vivo; 2023; 37(4):1751-1759. PubMed ID: 37369516
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids.
Elbadawy M; Hayashi K; Ayame H; Ishihara Y; Abugomaa A; Shibutani M; Hayashi SM; Hazama S; Takenouchi H; Nakajima M; Tsunedomi R; Suzuki N; Nagano H; Shinohara Y; Kaneda M; Yamawaki H; Usui T; Sasaki K
Biomed Pharmacother; 2021 Oct; 142():112043. PubMed ID: 34411919
[TBL] [Abstract][Full Text] [Related]
11. Patient-Derived Organoid Model in the Prediction of Chemotherapeutic Drug Response in Colorectal Cancer.
Hao M; Cao Z; Wang Z; Xin J; Kong B; Xu J; Zhang L; Chen P
ACS Biomater Sci Eng; 2022 Aug; 8(8):3515-3525. PubMed ID: 35696669
[TBL] [Abstract][Full Text] [Related]
12. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
[TBL] [Abstract][Full Text] [Related]
13. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
Ooft SN; Weeber F; Dijkstra KK; McLean CM; Kaing S; van Werkhoven E; Schipper L; Hoes L; Vis DJ; van de Haar J; Prevoo W; Snaebjornsson P; van der Velden D; Klein M; Chalabi M; Boot H; van Leerdam M; Bloemendal HJ; Beerepoot LV; Wessels L; Cuppen E; Clevers H; Voest EE
Sci Transl Med; 2019 Oct; 11(513):. PubMed ID: 31597751
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin: a new agent for colorectal cancer.
Pelley RJ
Curr Oncol Rep; 2001 Mar; 3(2):147-55. PubMed ID: 11177747
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.
Kotani D; Yoshino T; Kotaka M; Kawazoe A; Masuishi T; Taniguchi H; Yamazaki K; Yamanaka T; Oki E; Muro K; Komatsu Y; Bando H; Satake H; Kato T; Tsuji A
Invest New Drugs; 2021 Dec; 39(6):1649-1655. PubMed ID: 34019214
[TBL] [Abstract][Full Text] [Related]
19. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer.
Dost Gunay FS; Kırmızı BA; Ensari A; İcli F; Akbulut H
Clin Colorectal Cancer; 2019 Jun; 18(2):e244-e250. PubMed ID: 30670344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
